CN Patent

CN118632696A — 包含fgfr抑制剂和kras抑制剂的组合疗法

Assigned to Incyte Corp · Expires 2024-09-10 · 2y expired

What this patent protects

本公开涉及治疗癌症的方法，所述方法通过施用作为成纤维细胞生长因子受体(FGFR)抑制剂的化合物与克尔斯滕大鼠肉瘤(Kirsten rat sarcoma，KRAS)抑制剂的组合来实施。

USPTO Abstract

本公开涉及治疗癌症的方法，所述方法通过施用作为成纤维细胞生长因子受体(FGFR)抑制剂的化合物与克尔斯滕大鼠肉瘤(Kirsten rat sarcoma，KRAS)抑制剂的组合来实施。

Drugs covered by this patent

Patent Metadata

Patent number
CN118632696A
Jurisdiction
CN
Classification
—
Expires
2024-09-10
Drug substance claim
No
Drug product claim
No
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.